BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

929 related articles for article (PubMed ID: 28028830)

  • 1. Retrospective Evaluation of Postoperative Adverse Drug Events in Patients Receiving Rivaroxaban After Major Orthopedic Surgery Compared with Standard Therapy in a Community Hospital.
    Cieri NE; Kusmierski K; Lackie C; Van Opdorp A; Hassan AK
    Pharmacotherapy; 2017 Feb; 37(2):170-176. PubMed ID: 28028830
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rivaroxaban for thromboprophylaxis among patients recently hospitalized for acute infectious diseases: a subgroup analysis of the MAGELLAN study.
    Cohoon KP; De Sanctis Y; Haskell L; McBane RD; Spiro TE
    J Thromb Haemost; 2018 Jul; 16(7):1278-1287. PubMed ID: 29753308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing Length of Stay Between Patients Taking Rivaroxaban and Conventional Anticoagulants for Treatment of Venous Thromboembolism.
    Desai A; Desai A; Calixte R; Aparnath M; Hindenburg A; Salzman S; Mathew JP
    Lung; 2016 Aug; 194(4):605-11. PubMed ID: 27192990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A RCT study of Rivaroxaban, low-molecular-weight heparin, and sequential medication regimens for the prevention of venous thrombosis after internal fixation of hip fracture.
    Tang Y; Wang K; Shi Z; Yang P; Dang X
    Biomed Pharmacother; 2017 Aug; 92():982-988. PubMed ID: 28605879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Postoperative Bleeding in Total Hip and Knee Arthroplasty Patients Receiving Rivaroxaban or Enoxaparin.
    Ricket AL; Stewart DW; Wood RC; Cornett L; Odle B; Cluck D; Freshour J; El-Bazouni H
    Ann Pharmacother; 2016 Apr; 50(4):270-5. PubMed ID: 26783354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
    Coleman CI; Bunz TJ; Turpie AGG
    Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of timing of prophylaxis, type of anesthesia, and use of mechanical methods on outcome in major orthopedic surgery - subgroup analyses from 17,701 patients in the XAMOS study.
    Haas S; Holberg G; Kreutz R; Lassen MR; Mantovani L; Haupt V; Vogtländer K; Turpie AG
    Vasc Health Risk Manag; 2016; 12():209-18. PubMed ID: 27274266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective Evaluation of Postoperative Bleeding Events in Patients Receiving Rivaroxaban After Undergoing Total Hip and Total Knee Arthroplasty: Comparison with Clinical Trial Data.
    Wood RC; Stewart DW; Slusher L; El-Bazouni H; Cluck D; Freshour J; Odle B
    Pharmacotherapy; 2015 Jul; 35(7):663-9. PubMed ID: 26095331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rivaroxaban or Enoxaparin in Nonmajor Orthopedic Surgery.
    Samama CM; Laporte S; Rosencher N; Girard P; Llau J; Mouret P; Fisher W; Martínez-Martín J; Duverger D; Deygas B; Presles E; Cucherat M; Mismetti P;
    N Engl J Med; 2020 May; 382(20):1916-1925. PubMed ID: 32223113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Venous Thromboembolism Prophylaxis After TKA: Aspirin, Warfarin, Enoxaparin, or Factor Xa Inhibitors?
    Bala A; Huddleston JI; Goodman SB; Maloney WJ; Amanatullah DF
    Clin Orthop Relat Res; 2017 Sep; 475(9):2205-2213. PubMed ID: 28569372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and safety of rivaroxaban and warfarin in patients with unprovoked venous thromboembolism: a propensity-matched nationwide cohort study.
    Larsen TB; Skjøth F; Kjældgaard JN; Lip GYH; Nielsen PB; Søgaard M
    Lancet Haematol; 2017 May; 4(5):e237-e244. PubMed ID: 28411120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rivaroxaban Versus Warfarin for Stroke Prevention and Venous Thromboembolism Treatment in Extreme Obesity and High Body Weight.
    Perales IJ; San Agustin K; DeAngelo J; Campbell AM
    Ann Pharmacother; 2020 Apr; 54(4):344-350. PubMed ID: 31672028
    [No Abstract]   [Full Text] [Related]  

  • 13. Rivaroxaban and Apixaban for Initial Treatment of Acute Venous Thromboembolism of Atypical Location.
    Janczak DT; Mimier MK; McBane RD; Kamath PS; Simmons BS; Bott-Kitslaar DM; Lenz CJ; Vargas ER; Hodge DO; Wysokinski WE
    Mayo Clin Proc; 2018 Jan; 93(1):40-47. PubMed ID: 29217335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism.
    Wysokinski WE; Houghton DE; Casanegra AI; Vlazny DT; Bott-Kitslaar DM; Froehling DA; Hodge DO; Peterson LG; Mcbane RD
    Am J Hematol; 2019 Nov; 94(11):1185-1192. PubMed ID: 31378995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of rivaroxaban use in patients with gynecologic malignancies at an academic medical center: A pilot study.
    Signorelli JR; Gandhi AS
    J Oncol Pharm Pract; 2019 Mar; 25(2):362-368. PubMed ID: 29157146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative risk of major bleeding with rivaroxaban and warfarin: Population-based cohort study of unprovoked venous thromboembolism.
    Kohn CG; Bunz TJ; Beyer-Westendorf J; Coleman CI
    Eur J Haematol; 2019 Feb; 102(2):143-149. PubMed ID: 30328143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the appropriateness of dosing, indication and safety of rivaroxaban in a community hospital.
    Tellor KB; Patel S; Armbruster AL; Daly MW
    J Clin Pharm Ther; 2015 Aug; 40(4):447-51. PubMed ID: 26010016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of anticoagulation with rivaroxaban in trauma and acute care surgery: Complications and reversal strategies as compared to warfarin therapy.
    Myers SP; Dadashzadeh ER; Cheung J; Alarcon L; Kutcher M; Brown JB; Neal MD
    J Trauma Acute Care Surg; 2017 Mar; 82(3):542-549. PubMed ID: 28045742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics and Outcomes in Patients with Venous Thromboembolism Taking Concomitant Anti-Platelet Agents and Anticoagulants in the AMPLIFY Trial.
    Cohen AT; Agnelli G; Buller HR; Gallus A; Raskob GE; Sanders P; Thompson J; Weitz JI
    Thromb Haemost; 2019 Mar; 119(3):461-466. PubMed ID: 30650446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elective hip and knee arthroplasty and the effect of rivaroxaban and enoxaparin thromboprophylaxis on wound healing.
    Sindali K; Rose B; Soueid H; Jeer P; Saran D; Shrivastava R
    Eur J Orthop Surg Traumatol; 2013 May; 23(4):481-6. PubMed ID: 23412293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.